Barclays
HALO icon

Barclays’s Halozyme HALO Stock Holding History

Barclays’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,000
Closed -$15K – 7131
2018
Q4 		$15K Hold
1,000
– – ﹤0.01% 6022
2018
Q3 		$18K Hold
1,000
– – ﹤0.01% 6495
2018
Q2 		$17K Sell
1,000
-169,100
-99% -$3.2M ﹤0.01% 6269
2018
Q1 		$3.33M Buy
170,100
+168,600
+11,240% +$3.27M ﹤0.01% 1961
2017
Q4 		$30K Buy
+1,500
New +$27.6K ﹤0.01% 6069
2013
Q3 		– Sell
-248,100
Closed -$1.97M – 7493
2013
Q2 		$1.97M Buy
+248,100
New +$1.58M ﹤0.01% 2553

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's HALO Position: Q1 2026 in Review

Barclays reduced its Halozyme (HALO) stake by 18% in Q1 2026, selling an estimated $3.07M and leaving 193,242 shares worth $12.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1331.

Barclays first reported a position in HALO in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.6M in Q3 2025. 635 funds tracked by Wall St. Rank hold HALO as of Q1 2026.

  • Barclays held 193,242 shares of Halozyme worth $12.5M as of Q1 2026.
  • Barclays sold 43,522 Halozyme shares in Q1 2026, an estimated $3.07M.
  • Halozyme made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1331 holding.
  • Barclays first reported a position in Halozyme in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Halozyme position peaked at $22.6M in Q3 2025.
  • 635 funds tracked by Wall St. Rank held Halozyme as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.